Mounika Gangireddy
Hematology & Oncology · Washington, DCNPI 1376066852
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,022 of the $2,722 with a category attached, or 74.3%. It is spread thinly across 30 manufacturers, the largest accounting for just 18.8%. Reporting peaked in 2023 at $1,400 and has fallen 94.6% since, to $75 in 2025. That places this record below the midpoint for hematology & oncology clinicians in DC, where the typical reported total is $4,025.
Across 94 payments — averaging $28.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$513
- Incyte Corporation$288
- E.r. Squibb & Sons, L.L.C.$227
- AstraZeneca$183
- Jazz Pharmaceuticals Inc.$145
- Astellas Pharma US Inc$139
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,02274%
- Education$70026%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 15 | $513 |
| Incyte Corporation | 6 | $288 |
| E.r. Squibb & Sons, L.L.C. | 11 | $227 |
| AstraZeneca(2 entities) | 10 | $183 |
| Jazz Pharmaceuticals Inc. | 1 | $145 |
| Astellas Pharma US Inc | 3 | $139 |
| GSK | 1 | $120 |
| Sanofi | 5 | $118 |
| Lilly USA, LLC | 6 | $108 |
| Bristol Myers Squibb | 4 | $87 |
| Novartis | 4 | $82 |
| Sanofi-aventis U.S. LLC | 1 | $78 |
| Caris MPI, Inc. | 1 | $75 |
| Blueprint Medicines Corporation | 2 | $68 |
| Adaptive Biotechnologies Corporation | 2 | $68 |
| Bayer | 3 | $57 |
| Taiho Oncology, Inc. | 3 | $46 |
| AVEO Pharmaceuticals, Inc. | 2 | $40 |
| Pfizer | 2 | $39 |
| Eisai Inc. | 2 | $36 |
| Johnson & Johnson | 1 | $25 |
| G1 Therapeutics, Inc. | 1 | $24 |
| Ipsen Biopharmaceuticals, Inc | 1 | $23 |
| Epizyme, Inc. | 1 | $23 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Mirati Therapeutics, Inc. | 1 | $19 |
| Amgen | 1 | $19 |
| Agios Pharmaceuticals, Inc. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,722 in reported general payments places this provider in the 40th percentile of 69 hematology & oncology providers in District of Columbia.
See all hematology & oncology providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 30 | $518,731 |
| EliquisApixaban | 22 | $16,142 |
| Anastrozole | 78 | $1,891 |
| Prochlorperazine Maleate | 40 | $782 |
| Letrozole | 20 | $737 |
| Ondansetron OdtOndansetron | 26 | $722 |
| Dexamethasone | 58 | $677 |
| Tamoxifen Citrate | 11 | $364 |
| Gabapentin | 34 | $275 |
| Acyclovir | 14 | $257 |
| Oxycodone Hcl | 21 | $209 |
| Ondansetron Hcl | 17 | $198 |
| Hydroxyurea | 14 | $166 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 13 | $109 |
| Prednisone | 19 | $87 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $87 | $518,73130 claims |
| PfizerEliquis | $39 | $16,14222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 69 hematology & oncology providers in District of Columbia.
Other hematology & oncology in Washington
- Imadeddine TabbaraWashington$1.2M
- John MarshallWashington$525K
- Catherine BroomeWashington$504K
- Craig KesslerWashington$449K
- Benjamin WeinbergWashington$326K
- Claudine IsaacsWashington$241K
- Chul KimWashington$173K
- Christopher GallagherWashington$109K
- Neil ShahWashington$76K
- Vered StearnsWashington$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.